REVIEW ARTICLE

The clinical implications of platelet-rich fibrin on periodontal regeneration: A systematic review

Marwa Madi *, Ahmed M. Elakel

Department of Preventive Dental Sciences, College of Dentistry, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

Received 15 September 2020; revised 24 November 2020; accepted 1 December 2020
Available online 9 December 2020

KEYWORDS
Platelet-rich fibrin; PRF; Periodontal disease; Regeneration; Surgery; Clinical trial

Abstract  Objectives: Platelet concentrates have been shown to enhance periodontal regeneration when used as a treatment on their own or in conjunction with bone grafting materials. This systematic review aims to assess the effects of using platelet-rich fibrin (PRF), both alone and in combination with other conventionally used materials, on periodontal regeneration in clinical trials.

Materials and methods: A systematic electronic search was performed in the electronic databases MEDLINE (PubMed), Scopus, and Web of Science. Specifically, we searched for English language articles published between 2009 and 2019 that conducted in-human studies and included a summary of the results. Our primary search yielded 220 articles, and of these, 110 were clinical studies. Forty-four articles were then selected for a full reading.

Results: Twenty-six randomized control trials (RCTs) met the inclusion criteria and were included in this review. Despite the differences between the reviewed studies, most revealed the ability of PRF to promote periodontal wound healing. The positive effects of PRF were observed in clinical criteria, such as reductions in pocket probing depth (PD) and increases in clinical attachment level (CAL), as well as in the degree of defect bone fill, which was determined either radiographically or by surgical re-entry.

Conclusions: Additional studies are needed to compare the clinical outcomes of various PRF application procedures and establish standardized protocols for treating periodontal disease with PRF.

© 2020 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author at: Department of Preventive Dental Sciences, Periodontology Division. College of Dentistry, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia.
E-mail address: mimadi@iau.edu.sa (M. Madi).
Peer review under responsibility of King Saud University.

https://doi.org/10.1016/j.sdentj.2020.12.002
1013-9052 © 2020 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

The field of maxillofacial surgery has been greatly advanced by the introduction of autologous platelets and their production via different techniques. Platelet concentrates are made by centrifuging the patient’s blood. When used either alone or in combination with bone grafts, they have a significant impact on periodontal regeneration (Ehrenfest et al., 2014). Platelet concentrates have been classified into four main categories, based upon their leucocyte and fibrin content: pure platelet-rich plasma (P-PRP), leucocyte-platelet-rich plasma (L-PRP), pure platelet-rich fibrin (P-PRF), and leucocyte-platelet-rich fibrin (L-PRF). These classes can be further divided into two generations: the first generation includes platelet-rich plasma (PRP), while the second generation consists of platelet-rich fibrin, such as Choukroun’s PRF (Ehrenfest et al., 2009).

PRP was first introduced by Marx et al. (1998), who combined PRP with cancellous bone to augment mandibular defects. Their study revealed that adding PRP to bone grafts accelerated bone regeneration and improved bone quality. PRP releases various growth factors, thereby providing the healing site with an effective growth factor delivery system. These growth factors crucially assist the cells that contribute to the healing process, including osteoblasts, fibroblasts, and cementoblasts, which each promote rapid tissue regeneration (Anitua et al., 2007).

The second generation platelet derivation, PRF, first appeared in France in 2001 (Choukroun et al., 2006). PRF consists of a patient-derived fibrin matrix, which is rich in thrombocytes and white blood cells. The primary difference between PRP and PRF is that PRF does not require any additives, such as anticoagulants, thrombin, or any other gelling agents (Dohan et al., 2006). Additionally, naturally polymerized PRF clots more effectively than PRP due to its slow, sustained release of growth factors over an average of 7-days following the onset of the wound. PRP, meanwhile, quickly releases a large quantity of growth factors during the first 48 h, resulting in a lighter fibrin clot (Dohan Ehrenfest et al., 2009; Passaretti et al., 2014).

This systematic review aims to investigate the value of using PRF either on its own or combined with conventionally used materials for periodontal regeneration in clinical trials.

2. Methodology

2.1. Search strategy

A systematic electronic search was performed in the electronic databases MEDLINE (PubMed), Scopus, and Web of Science. The reviewers searched for papers written in English and published from January 2009 to 2019 using the following terms: “Platelet rich fibrin” AND “Periodontal regeneration” OR “PRF” AND “Periodontal surgery.” This review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) and the issued identification number CRD42020215523. Our primary focus was to assess the efficacy of using PRF either alone or in combination with conventionally used materials for periodontal regeneration in periodontitis patients based on observed clinical outcomes, such as PD, CAL, and the level of bone fill.

The search strategy was divided into two phases. In the first phase, two reviewers (M.M. and A.E.) independently screened the titles and abstracts generated by the search. When publications did not fulfill the inclusion criteria, they were excluded upon the reviewers’ agreement. Any disagreement between the two reviewers was resolved by discussion.

During the second phase, the eligible articles’ full texts were obtained and examined by both reviewers. The articles that fulfilled all selection criteria were processed for data extraction. This review was performed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

2.2. Eligibility criteria

To be eligible for inclusion, publications had to meet the following criteria: they must (1) contain original research published in English; (2) conduct an RCT; (3) include test and control groups with periodontal defects; (4) report data outcomes, CAL, PD, and/or defect fill; and (5) conduct a randomized clinical trial, clinical study, or comparative study. Prospective and retrospective cohort studies, letters to editors, reviews, case series, case reports, and in vivo and in vitro studies were not included.
2.3. Risk of bias assessment

The reviewers independently assessed the risk of bias for each study, and conflicts were discussed based on the protocols outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins, 2011). Five bias domains were established: bias arising from the randomization process (D1), bias due to deviations from intended interventions (D2), bias due to missing outcome data (D3), bias in outcome measurements (D4), and bias in the selection of the reported result (D5). Studies were considered to have a “low risk of bias” if none of the above domains were present. If at least one domain raised questions or concerns, studies were given the label “raised some concerns/moderate risk,” while studies were designated as “high risk” if at least one domain exhibited a high degree of bias or if several concerns were present in multiple domains. The Cochrane Collaboration tool was then used to generate the quality risk-of-bias assessment results’ chart.

3. Results

3.1. Search and selection

The electronic search and the initial screening yielded 220 articles for consideration. After excluding duplicated titles, 196 articles remained. These articles were then searched using the terms “Clinical study” OR “Clinical trial” OR “Comparative study” AND “Human study.” Following this search, 110 articles remained. We then screened titles and abstracts to remove articles that were either unrelated to our objective or did not report clinical periodontal findings. A total of 44 articles remained. These articles were selected for a complete reading, and any doubt regarding a study’s inclusion in this review was resolved by the reviewers’ agreement to include or exclude that particular study.

Of the 44 articles, 18 were excluded. Two of these articles investigated gingival recession, one focused on dental implants, two discussed palatal wound healing, two considered maxillary sinus augmentation, four examined third molar extraction and osteonecrosis, and seven explored ridge augmentation and socket preservation. Ultimately, twenty-six randomized RCTs fulfilled the inclusion criteria and were selected for full text reviews (Fig. 1). The risk of bias assessment determined that twenty studies had a low risk of bias, three had a moderate risk, and three had a high risk (Fig. 2). These studies were designated as high risk due to concerns or missing information regarding D2, D3, D4, and D5.

Of the 26 fully reviewed studies, six used PRF compared to open flap debridement (OFD) alone (Arabaci et al., 2017; Bajaj et al., 2017; Kizildag et al., 2018; Pradeep et al., 2012; Sharma and Pradeep, 2011a; Thorat et al., 2011). Two studies examined the application of PRF alone for treating class II furcation involvement (Bajaj et al., 2013; Sharma and Pradeep, 2011a). Of the studies that used PRF in combination with other materials, one added PRF to a collagen membrane (Panda et al., 2016). Seven used PRF together with bone graft materials to treat intrabony defects (IBDs; Agarwal et al., 2016; Chatterjee et al., 2017; Galav et al., 2016; Gamal et al., 2016; Lekovic et al., 2012; Pradeep et al., 2017; Sezgin et al., 2017). An additional four studies combined PRF with other regenerative agents for treating class II furcation involvement (Biswas et al., 2016; Kanoriya et al., 2017; Pradeep et al., 2016; Sharma and Pradeep, 2011a). Finally, in five studies, PRF was combined with either topical therapeutic agents (Kanoriya et al., 2016; Martande et al., 2016; Pradeep et al., 2015) or with...
| Author/ Year | Type of study | Sample size | Defect type | Study groups | Assessed clinical parameters | Results |
|--------------|--------------|-------------|-------------|--------------|------------------------------|---------|
| Kizildağ et al. 2018 | Split mouth RCT | 16 patients with 32 sites | Intra-bony defects IBD | Gp I: leukocyte-platelet-rich fibrin (L-PRF) + (OFD) GpII: OFD alone | PD and CAL were measured at baseline and 6 months. GCF BMP-2 and IL-1 assessed at baseline, 1, 2, and 4 weeks. | Group I showed significant PD reduction and CAL gain, increased BMP-2 and IL-1, than group II. |
| Pradeep et al. 2017 | RCT | 62 patients with 90 sites | 3-Wall IBD | Gp I: PRF + OFD Gp II: PRF + HA + OFD Gp III: OFD (controls) | PD, CAL, IBD depth, and defect fill percentage were measured at baseline and 9 months | Gp I showed better results than Gp II and Gp III. |
| Patel et al. 2017 | Split mouth RCT | 13 patients with 13 sites bilaterally | IBD | Gp I: PRF + OFD Gp II: OFD alone | PD, CALrv and BF. Evaluation was done at 6, 9, and 12 months. | PRF group also showed significant soft tissue healing and reduction in PD. BF was 45.18% ± 7.57% for Gp I and 21.6% ± 9.3% for GpII. |
| Bajaj et al. 2017 | Split mouth RCT | 17 patients with 27 sites bilaterally | 3-Wall IBD in AP. | Gp I: PRF + OFD Gp II: OFD alone | PD, CAL and radiographic bone fill and defect depth decrease. | Gp I showed significant reduction in PD, CAL and increased bone fill. |
| Arabaci et al. 2017 | Split mouth RCT | 26 patients with 52 sites | IBD | Gp I: PRF + OFD Gp II: OFD alone | PD, CAL, FGF-2, TGF-B, and PDGF-BB | Gp I showed significant reduction in PD, CAL and more expression of the evaluated growth factors. |
| Sezgin et al. 2017 | RCT | 21 patients with 15 sites bilaterally | IBD | Gp I: ABBM alone (control group) Gp II: ABBM-PRF | PI, GI, PD, GR, CAL, VBL, DD, and defect angle were recorded at baseline and 6 months | Both therapies are effective in the treatment of intra-bony defects. |
| Kanoriya et al. 2017 | RCT | 72 patients with 72 sites | Mandibular Fissure Defects | Gp I: access therapy only Gp II: access therapy + PRF Gp III: access therapy + PRF + 1% ALN | PI, GI, PD, GR, CAL, VBL, DD, and defect angle were recorded at baseline and 6 months | Gp III showed more RDF (56.01% ± 2.64%) than Gp II (49.43% ± 3.70%) and Gp I (10.25% ± 3.66%) at 9 months. |
| Chatterjee et al., 2017 | RCT | 38 patients with 90 sites | IBD | Gp I: OFD Gp II: OFD + PRF Gp III: OFD + titanium TPRF | PI, GI, PD, GR, CAL, VBL, DD, and defect angle were recorded at baseline and 6 months | No significant difference between groups II and III. |
| Galav et al. 2016 | RCT | 20 patients with 20 sites | IBD | Gp I: PRF Gp II: ABG, autogenous bone grafting | PPAD, CAL, and DD were assessed at baseline and 9 months | Gp II showed significantly greater RBF (30.34%) and surgical reentry bone fill 65.31%, compared to PRF 20.22% and 43.64%. |
| Kanoriya et al. 2016 | RCT | 96 patients with 90 sites | IBD | Gp I: access therapy only Gp II: access therapy + PRF Gp III: access therapy + PRF + 1% ALN | Site-specific PI, MSI, BI, PD, CAL, GML, and IBDR were measured at baseline and 9 months | Gp III showed greater PD reduction and CAL gain. |
| Pradeep et al. 2016 | RCT | 110 patients with 105 sites | IBD | Gp I: OFD Gp II: OFD + PRF Gp III: OFD + PRF + 1.2% RSV gel | PI, mSBI, PD, CAL and IBD depth were assessed at baseline and 9 months | Gp III showed significant improvement in all parameters other than 2 groups. |
| Aydemir et al., 2016 | Split mouth RCT | 56 patients with 24 and 25 sites bilaterally | IBD | Gp I: EMD Gp II: EMD + PRF. | CAL, PD, GR, DD, DW and DA were measured at baseline and 6 months | Both groups showed similar results in all parameters. |
| Martande et al., 2016 | RCT | 96 patients with 32 sites | IBD | Gp I: OFD + PRF Gp II: | Site-specific PI, mSBI, PD, | Gp II showed better results than Gp I and III. |
| Author/Year | Type of study | Sample size | Defect type | Study groups | Assessed clinical parameters | Results |
|-------------|---------------|-------------|-------------|--------------|-----------------------------|---------|
| Biswas et al. 2016 | RCT | 15 patients with 20 sites | Furcation grade II | Gp I: Bioactive Glass (Putty) Gp II: PRF | PD, GI, PI, CAL, and horizontal probing depth of furcation involvement | IBD was 50.96% ± 4.88% for GP II compared with GP I (47.91% ± 4.79%), and a greater reduction than GP III (5.54% ± 1.71%). Both groups showed similar clinical improvements, however, PD were more reduced in BG group than PRF. Gp I showed more defects fill than GP II. |
| Panda et al. 2016 | Split mouth RCT | 16 patients with 16 sites bilaterally | IBD | Gp I: PRF + resorbable collagen membrane Gp II: collagen membranes alone | PD, GI, PI, CAL, GML and RDD were assessed at baseline and after 9 months. | No significant clinical differences were reported among the three groups during the two observation periods. |
| Gamal et al. 2016 | RCT | 30 patients with 30 sites | IBD | Gp I: PRF Gp II: PRGF Gp III: Xenografts platelets rich in growth factors (PRGF) | PD, CAL, IBD, VEGF and PDGF-BB were assessed at days 1, 3, 7, 14, 21, and 30 days. | |
| Agarwal et al. 2016 | Split mouth RCT | 32 patients with 32 sites bilaterally | IBD | Gp I: PRF + DFDBA Gp II: DFDBA + saline | PD, CAL, REC, and RBF were measured at baseline and 12-months | Gp II showed better results than Gp I regarding PD, CAL, and REC. Gp I showed 3.50 ± 0.67 bone than Gp II 2.49 ± 0.64 mm. Better results were observed for Gp III and II than I. Significant Percentage bone fill was found for Gp III and II (61.94% ± 3.54%, 54.69% ± 1.93%) than Gp I (10.09% ± 4.28%). Gp IV better clinical improvement and more defect depth reduction compared to other groups. |
| Pradeep et al. 2016 | RCT | 120 patients with 105 sites | Grade II furcation defects | Gp I: OFD + placebo gel Gp II: PRF + HA + OFD Gp III: 1.2 mg RSV gel + PRF + HA + OFD | PD, rvCAL, rhCAL, IBDD, and percentage DF were recorded at baseline and after 9 months. | |
| Pradeep et al. 2015 | RCT | 120 patients with 120 sites | IBD | Gp I: OFD Gp II: OFD + PRF Gp III: OFD + 1% MF Gp IV: OFD + PRF + 1% MF | PI, mSBI, PD, RAL, GML, and IBDD were evaluated at baseline and 9 months. | Both groups showed intrabony defects regeneration however, Gp I showed significant defect fill (43.07% ± 12.21) than Gp II (32.41% ± 14.61). The use of autologous PRF or PRP were both effective in the treatment of furcation defects with uneventful healing of sites. Both Gp I and II showed better PD reduction and CAL gain Significant bone fill was found for Gp I (55.41% ± 11.3%9) and Gp II (56.85% ± 14.01%) compared with Gp III (1.56% ± 15.12%). |
| Gupta et al. 2014 | RCT | 30 patients with 44 sites | IBD | Gp I: Emdogain EMD Gp II: PRF | PD, CAL, IBDD and IBDA were evaluated at baseline and after 6 months. | |
| Bajaj et al. 2013 | RCT | 72 patients with 72 sites | Grade II furcation defects | Gp I: OFD + PRF Gp II: OFD + PRP Gp III: OFD | PD, rvCAL, hCAL and GML were measured at baseline and after 9 m. | Both groups showed intrabony defects regeneration however, Gp I showed significant defect fill (43.07% ± 12.21) than Gp II (32.41% ± 14.61). The use of autologous PRF or PRP were both effective in the treatment of furcation defects with uneventful healing of sites. Both Gp I and II showed better PD reduction and CAL gain Significant bone fill was found for Gp I (55.41% ± 11.3%) and Gp II (56.85% ± 14.01%) compared with Gp III (1.56% ± 15.12%). |
| Pradeep et al. 2012 | RCT | 54 patients with 90 sites | IBD | Gp I: PRF + OFD Gp II:PRF + OFD Gp III: OFD | PD, CAL, IBD, and percentage DF were assessed at baseline and after 9 months. | |
| Lekovic et al. 2012 | RCT | 17 patients with 17 sites bilaterally | IBD | Gp I: PRF alone Gp II: PRF + BPBM xenograft | PD, CAL and DF. Surgical re-entry after 6 months. | Gp II showed significant PD reduction and CAL gain than Gp I. Defect fill was greater in Gp II (4.06 ± 0.8) than in the Gp I (2.21 ± 0.68 mm) Gp I showed significant defect fill than GP II (46.92% versus 28.66%). |
| Thorat et al. 2011 | RCT | 32 patients with 32 sites | IBD | Gp I: OFD + PRF Gp II : OFD | PI, PD, CAL, SBI, GML, and IBDD fill were recorded at baseline and 9 months. | (continued on next page) |
enamel matrix derivatives (EMD; Aydemir Turkal et al., 2016; Gupta et al., 2014).

4. Discussion

This systematic review covers the application of PRF over the last 10 years and highlights the clinical benefits of using PRF as a means of enhancing periodontal regeneration. Table 1 shows the advantage of adding PRF in conjunction with OFD to treat IBDs.

Using PRF after OFD (Arabaci et al., 2017; Bajaj et al., 2017; Kizildag et al., 2018; Pradeep et al., 2012; Sharma and Pradeep, 2011a; Thorat et al., 2011) have resulted in CAL gains, PD reductions, and bone fill level increases compared to performing OFD alone. These results could be attributed to the ability of PRF to enhance the proliferation and differentiation of cells such as osteoblasts, fibroblasts, and cementoblasts at the healing site, thus promoting tissue regeneration in addition to the repair that OFD offers alone. The process of tissue regeneration occurs when the sustained release of the applied PRF’s 3D fibrin matrix produces a local concentration sufficient to form autologous PRF, which then acts as an effective substitute for any recombinant sources of growth factors or grafting materials. Combining medical drugs such as 1% metformin (Pradeep et al., 2015), 1.2% atorvastatin (Martande et al., 2016), or 1.2% rosuvastatin (RSV) gel (Pradeep et al., 2016) with PRF have shown better results than using either these medications or PRF alone. However, Aydemir Turkal et al. (2016) observed comparable results in CAL gain, PD reduction, and defect dimension decrease between patients treated with a combination of EMD and PRF and those treated solely with EMD. Furthermore, Gupta et al. (2014) observed significant bone regeneration and defect fill for patients treated with Emdogain rather than PRF.

Clinical and radiographic measurements revealed that furcation defect sites treated with a combination of PRF and OFD showed better results compared to those treated solely with OFD. It is worth mentioning that utilizing a split-mouth design overcomes human factors that could influence the results. In their study comparing the effects of PRF with those of OFD, Sharma and Pradeep, 2011b measured the mean changes in gingival margin levels 9 months after treatment. They observed a mean change of 0.3 mm in the group treated with PRF, compared with a change of 0.7 mm in the control group. The results indicated that placing the PRF membrane slightly coronal to the gingival margin prevented gingival recession. As a material that promotes healing, PRF was shown to stimulate gingival connective tissue and provide the root surface with the fibronectin and vitronectin mandatory for cell migration. Moreover, PRF was found to stimulate healing when placed after OFD compared to using OFD alone. Adding PRF to bone grafts was also shown to accelerate healing more than treatments that relied solely on bone grafts. This result can be attributed to PRF’s 3D fibrin network structure, which is absent in first generation PRP but allows PRF to be retained in the periodontal defect, acting as a slow-release local delivery system for growth factors.

When PRF was combined with porous hydroxyapatite (HA) and RSV 1.2 mg in situ gel to treat class II furcation defects (Pradeep et al., 2016), the most significant PD reduction (4.62 ± 1.03 mm), CAL gain (4.17 ± 0.70 mm), IBD depth reduction (3.68 ± 0.32 mm), and bone defect fill (61.94% ± 5.72%) were observed for the combination of 1.2 mg RSV gel combined with PRF and BG. This finding could be attributed to RSV’s ability to decrease inflammatory markers, effectively reducing inflammation and gingival bleeding. Moreover, statins inhibit the osteoclastic differentiation that, in turn, favors bone formation and reduces bone resorption.
Several studies have focused on the efficacy of using PRF to treat IBDs. Lekovic et al. (2012) and Agarwal et al. (2016) both concluded that PRF accelerated the effect of bone grafts and improved the clinical parameters and apical bone fill in patients with IBDs. Similarly, Bajaj et al. (2017) observed a mean reduction in the same clinical parameters in treating patients with aggressive periodontitis with PRF compared to the control group treated with OFD alone. Pradeep et al. (2017) showed that the addition of PRF resulted in a significantly higher percentage of bone fill, which subsequently increased the regenerative effects of porous HA. Sezgin et al. (2017) also confirmed the positive effects of combining PRF with anorganic bovine bone mineral (ABBM) through a RCT that included 15 cases of IBDs. They noted a significant reduction regarding clinical and radiographic parameters. Meanwhile, Chatterjee et al. (2017) divided 32 paired IBDs in 16 patients. They treated their test group with a resorbable collagen membrane combined with PRF, while the control group was treated with collagen alone, and they reported a statistical significance in the clinical and radiographic improvements for the test group over the control. In another study, Agarwal et al. (2016) evaluated parameters. Meanwhile, Chatterjee et al. (2017) divided 90 patients with IBDs into the following groups: those treated with OFD alone (group I), those treated with OFD combined with autologous PRF (group II), and those treated with the combination of OFD and titanium-prepared PRF (group III). Group I showed less improvement when compared to groups II and III in clinical measurements, while no statistically significant difference was noted between groups II and III. Panda et al. (2016) found similar results when examining 30 patients with chronic periodontitis. When the group treated with PRF/DFDBA was compared to the group given DFDBA/saline at baseline and at a 12-month evaluation, all clinical and radiographic parameters showed favorable results in the group that received PRF.

While the studies discussed above each point to the beneficial effects of PRF, other researchers have concluded that PRF does not enhance the treatment of IBDs. For instance, Galav et al. (2016) tested the capability of using only PRF to treat IBDs in patients with chronic periodontitis. They determined that autogenous bone grafts showed higher radiographic bone fill measurements (30.34%) than treatments with PRF (20.22%). At the same time, Gamal et al. (2016) concluded that platelet concentrate did not add any significant clinical or radiographic effects when used with xenogeneic grafts.

5. Conclusion

Although the reviewed studies differ in their application of PRF and the manipulation protocols used in periodontal surgery, all contain a common factor: the ability of PRF to promote periodontal wound healing, as measured by clinical criteria (e.g., PD reduction and CAL gain) as well as increased levels of defect bone fill, which was investigated either graphically or by surgical re-entry. We recommend that future clinical studies compare various PRF preparations and application protocols to gauge their simplicity of use and determine any significant differences these preparations and protocols may have on clinical outcomes.

Ethical statement

No ethical approval was needed for this Review study.

Funding

This research did not receive any specific grant from funding agencies.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Agarwal, A., Gupta, N.D., Jain, A., 2016. Platelet rich fibrin combined with decalcified freeze-dried bone allograft for the treatment of human intrabony periodontal defects: a randomized split mouth clinical trial. Acta Odontol. Scand. 74, 36–43.

Anitura, E., Sanchez, M., Orive, G., Andia, I., 2007. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials 28, 4551–4560.

Arabaci, T., Kose, O., Albayrak, M., Cicék, Y., Kızıldag, A., 2017. Advantages of Autologous Platelet-Rich Fibrin Membrane on Gingival Crevicular Fluid Growth Factor Levels and Periodontal Healing: A Randomized Split-Mouth Clinical Study. J. Periodontol. 88, 771–777.

Aydemin Turkal, H., Demirer, S., Dolgun, A., Kececi, H.G., 2016. Evaluation of the adjunctive effect of platelet-rich fibrin to enamel matrix derivative in the treatment of intrabony defects. Six-month results of a randomized, split-mouth, controlled clinical study. J. Clin. Periodontol. 43, 955–964.

Bajaj, P., Agarwal, E., Rao, N.S., Naik, S.B., Pradeep, A.R., Kalra, N., Priyanka, N., Kumari, M., 2017. Autologous Platelet-Rich Fibrin in the Treatment of 3-Wall Intrabony Defects in Aggressive Periodontitis: A Randomized Controlled Clinical Trial. J. Periodontol. 88, 1186–1191.

Bajaj, P., Pradeep, A.R., Agarwal, E., Rao, N.S., Naik, S.B., Priyanka, N., Kalra, N., 2013. Comparative evaluation of autologous platelet-rich fibrin and platelet-rich plasma in the treatment of mandibular degree II furcation defects: a randomized controlled clinical trial. J. Periodontal Res. 48, 573–581.

Bishara, S., Sambashiviah, S., Kulal, R., Bihan, S., Kurtzman, G.M., 2016. Comparative evaluation of bioactive glass (putty) and platelet rich fibrin in treating furcation defects. J. Oral Implantol. 42, 411–415.

Chatterjee, A., Pradeep, A.R., Garg, V., Yajamanya, S., Ali, M.M., Priya, V.S., 2017. Treatment of periodontal intrabony defects using autologous platelet-rich fibrin and titanium platelet-rich fibrin: a randomized, clinical, comparative study. J. Investig. Clin. Dent. 8, e12231.

Choukroun, J., Diss, A., Simonpieri, A., Girard, M.-O., Schoeffler, C., Dohan, S.L., Dohan, A.J.J., Mouhyi, J., Dohan, D.M., 2006. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV: clinical effects on tissue healing. Oral Surgery, Oral Med. Oral Pathol. Oral Radiol. Endodontology 101, c56–c60.

Dohan, D.M., Choukroun, J., Diss, A., Dohan, S.L., Dohan, A.J.J., Mouhyi, J., Gogly, B., 2006. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surgery, Oral Med. Oral Pathol. Oral Radiol. Endodontology 101, c37–c44.

Dohan Ehrenfest, D.M., de Peppo, G.M., Doglioli, P., Sammartino, G., 2009. Slow release of growth factors and thrombospordin-1 in...
Choukroun’s platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth factors 27, 63–69.

Ehrenfest, D.M.D., Andia, I., Zumstein, M.A., Zhang, C.-Q., Pinto, N.R., Bielecki, T., 2014. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. Muscles. Ligaments Tendons J. 4, 3.

Ehrenfest, D.M.D., Rasmusson, L., Albrektsson, T., 2009. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF). Trends Biotechnol. 27, 158–167.

Galav, S., Chandrashekar, K.T., Mishra, R., Tripathi, V., Agarwal, R., Galav, A., 2016. Comparative evaluation of platelet-rich fibrin and autogenous bone graft for the treatment of intrabony defects in chronic periodontitis: Clinical, radiological, and surgical reentry. Indian J. Dent. Res. 27, 502.

Gamal, A.Y., Abdel Ghaffar, K.A., Alghewzy, O.A., 2016. Crevicular fluid growth factors release profile following the use of platelet-rich fibrin and plasma rich growth factors in treating periodontal intrabony defects: A randomized clinical trial. J. Periodontol. 87, 654–662.

Gupta, S.J., Jhingran, R., Gupta, V., Bains, V.K., Madan, R., Rizvi, I., 2014. Efficacy of platelet-rich fibrin vs. enamel matrix derivative in the treatment of periodontal intrabony defects: a clinical and cone beam computed tomography study. J. Int. Acad. Periodontol. 16, 86.

Higgins, J.P., Altman, D.G., Gøtzsche, P.C., Juni, P., Moher, D., Oxman, A.D., Sterne, J.A., 2011. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928.

Kanortiya, D., Pradeep, A.R., Garg, V., Singhal, S., 2017. Mandibular degree II furcation defects treatment with platelet-rich fibrin and 1% alendronate gel combination: A randomized controlled clinical trial. J. Periodontol. 88, 250–258.

Kanortiya, D., Pradeep, A.R., Singhal, S., Garg, V., Guruprasad, C.N., 2016. Synergistic approach using platelet-rich fibrin and 1% alendronate for intrabony defect treatment in chronic periodontitis: a randomized clinical trial. J. Periodontol. 87, 1427–1435.

Kızıldağ, A., Çiček, Y., Arabaci, T., Köse, O., 2018. The effect of leukocyte-platelet-rich fibrin on bone morphogenetic protein-2 and insulin-like growth factor-1 levels in patients with chronic periodontitis: a randomized split mouth clinical trial. Growth Factors 36, 239–245.

Lekovic, V., Milinkovic, I., Aleksic, Z., Jankovic, S., Stankovic, P., Kenney, E.B., Camargo, P.M., 2012. Platelet-rich fibrin and bovine porous bone mineral vs. platelet-rich fibrin in the treatment of intrabony periodontal defects. J. Periodontal Res. 47, 409–417.

Martande, S.S., Kumari, M., Pradeep, A.R., Singh, S.P., Suket, D.K., Guruprasad, C.N., 2016. Platelet-rich fibrin combined with 1.2% atorvastatin for treatment of intrabony defects in chronic periodontitis: A randomized controlled clinical trial. J. Periodontol. 87, 1039–1046.

Marx, R.E., Carlson, E.R., Eichstaedt, R.M., Schimmele, S.R., Strauss, J.E., Georgoff, K.R., 1998. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surgery, Oral Med. Oral Pathol. Oral Radiol. Endodontology 85, 638–646.

Panda, S., Sankari, M., Satpathy, A., Jayakumar, D., Mozzati, M., Mortellaro, C., Gallesio, G., Taschieri, S., Del Fabbro, M., 2016. Adjunctive effect of autologous platelet-rich fibrin to barrier membrane in the treatment of periodontal intrabony defects. J. Craniofac. Surg. 27, 691–696.

Passaretti, F., Tia, M., D’esposito, V., Pascale, M. De, Corso, M. Del, Sepulveres, R., Liguoro, D., Valentino, R., Beguinot, F., Formisano, P., 2014. Growth-promoting action and growth factor release by different platelet derivatives. Platelets 25, 252–256.

Patel, G.K., Gaekwad, S.S., Gujjar, S.K., SC, V.K., 2017. Platelet-rich fibrin in regeneration of intrabony defects: a randomized controlled trial. J. Periodontol. 88, 1192–1199.

Pradeep, A.R., Bajaj, P., Rao, N.S., Agarwal, E., Naik, S.B., 2017. Platelet-rich fibrin combined with a porous hydroxyapatite graft for the treatment of 3-wall intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J. Periodontol. 88, 1288–1296.

Pradeep, A.R., Karvekar, S., Nagpal, K., Patnaik, K., Raju, A., Singh, P., 2016. Rosuvastatin 1.2 mg in situ gel combined with 1:1 mixture of autologous platelet-rich fibrin and porous hydroxyapatite bone graft in surgical treatment of mandibular class II furcation defects: A randomized clinical control trial. J. Periodontol. 87, 5–13.

Pradeep, A.R., Nagpal, K., Karvekar, S., Patnaik, K., Naik, S.B., Guruprasad, C.N., 2015. Platelet-rich fibrin with 1% metformin for the treatment of intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J. Periodontol. 86, 729–737.

Pradeep, A.R., Rao, N.S., Agarwal, E., Bajaj, P., Kumari, M., Naik, S.B., 2012. Comparative evaluation of autologous platelet-rich fibrin and platelet-rich plasma in the treatment of 3-wall intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J. Periodontol. 83, 1499–1507.

Sezgin, Y., Uraz, A., Taner, I.L., ÇULHAOĞLU, R., 2017. Effects of platelet-rich fibrin on healing of intra-bony defects treated with anorganic bovine bone mineral. Braz. Oral Res. 31.

Sharma, A., Pradeep, A.R., 2011a. Autologous platelet-rich fibrin in the treatment of mandibular degree II furcation defects: A randomized clinical trial. J. Periodontol. 82, 1396–1403.

Sharma, A., Pradeep, A.R., 2011b. Treatment of 3-wall intrabony defects in patients with chronic periodontitis with autologous platelet-rich fibrin: A randomized controlled clinical trial. J. Periodontol. 82, 1705–1712.

Thorat, M., Pradeep, A.R., Pallavi, B., 2011. Clinical effect of autologous platelet-rich fibrin in the treatment of intra-bony defects: a controlled clinical trial. J. Clin. Periodontol. 38, 925–932.